US2005208049A1PendingUtilityA1
Methods for treatment of HIV and other infections using a T cell or viral activator and anti-retroviral combination therapy
Individually held — no corporate assignee on recordPriority: Nov 24, 1997Filed: May 17, 2005Published: Sep 22, 2005
Est. expiryNov 24, 2017(expired)· nominal 20-yr term from priority
Inventors:Johnson Wong
C12N 2501/505A61P 31/18A61K 38/2013A61K 31/7072A61K 38/168C12N 2501/23A61K 38/162A61K 31/708A61K 2039/505C07K 2317/31C07K 16/2815A61K 38/2006C12N 2501/515A61K 39/395C12N 2501/06A61K 39/39541A61K 31/4412C07K 16/2809A61K 38/191A61K 40/46A61K 40/11A61K 2239/31C12N 5/0636
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed is a method for treating infection with a pathogen. The method involves administration of: (1) a substance which induces active pathogen replication in a cell latently infected with HIV and (2) an anti-pathogen drug. Also disclosed are methods for expanding CD4+ T cells from peripheral blood mononuclear cells isolated from human subjects in the presence of an antiretroviral drug and for treating HIV infection by infusing the expanded CD4+ cells into HIV-infected patients.
Claims
exact text as granted — not AI-modified1 - 21 . (canceled)
22 . An ex vivo method of expanding CD4+ T cells from a sample of peripheral blood mononuclear cells isolated from a human, comprising culturing a sample of peripheral blood mononuclear cells in cell culture system in the presence of a T cell mitogen and an antiretroviral drug.
23 . The method of claim 22 , wherein the T cell mitogen is a lectin or an antibody.
24 . The method of claim 22 , wherein the T cell mitogen is a bispecific monoclonal antibody having specificity for CD3 and CD8.
25 . A method for treating a patient infected with a pathogen, the method comprising:
(a) administering to the patient an amount of a cellular mitogen sufficient to induce activation of cells latently infected with the pathogen and induce replication of the pathogen; and (b) administering a therapeutically effective amount of an anti-pathogen drug.Join the waitlist — get patent alerts
Track US2005208049A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.